Identifying markers of treatment resistance in obsessive compulsive disorder
Cerebral and Cognitive Markers of Treatment Resistance in Obsessive-compulsive Disorder: Towards Personalization of Patient Care
This study is trying to find clues in the brain that can help understand why some people with obsessive compulsive disorder don’t respond to treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Centre Hospitalier Henri Laborit Academic / other |
| Locations | 1 site (Poitiers) |
| Trial ID | NCT05843604 on ClinicalTrials.gov |
What this trial studies
This observational study aims to define individual profiles of patients with treatment-resistant obsessive compulsive disorder (OCD) by utilizing functional MRI to identify cerebral and cognitive markers. The goal is to find indicators and predictors that can help understand therapeutic responses in these patients. Participants will be included regardless of the severity of their condition or their levels of executive functions, allowing for a comprehensive analysis of treatment resistance. The study will take place at the Centre Hospitalier Henri Laborit in Poitiers.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with obsessive compulsive disorder who exhibit treatment resistance.
Not a fit: Patients with diagnoses such as schizophrenic disorders or substance abuse may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of treatment-resistant OCD, potentially guiding more effective therapeutic strategies.
How similar studies have performed: While the approach of using functional MRI to study treatment resistance in OCD is innovative, similar studies have shown promise in identifying biomarkers for other psychiatric conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Obsessive compulsive disorder diagnosed according to Diagnostic and Statistical Manual 5 criteria (patients will be included regardless of the severity and resistance of their pathology and their levels of executive functions) * Understand and accept the constraints of the study * Be a beneficiary or affiliated to a Health Insurance scheme Exclusion Criteria: * Present one of the diagnoses according to the criteria of the DSM 5: schizophrenic disorders, substance abuse or dependence to a substance according to the criteria of the M.I.N.I. version 5.0 (Sheehan et al., 1998) * Generalized anxiety disorder, social anxiety, nicotine dependence and history of a major depressive episode are not exclusion criteria according to the M.I.N.I. version 5.0 (Sheehan et al., 1998) * Have a serious intercurrent pathology * Being a pregnant woman * Being a woman of childbearing age without effective contraception. * Being hospitalized under duress or on an outpatient basis in a care program * Being under judicial protection (reinforced curatorship, guardianship)
Where this trial is running
Poitiers
- Centre Hospitalier Henri Laborit — Poitiers, France (Recruiting)
Study contacts
- Study coordinator: Damien Doolub, MD
- Email: damien.doolub@ch-poitiers.fr
- Phone: +33 (0)5 16 61 18
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.